Home > Insider Trading > Filing (0001125345-20-000129)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1125345	Macrogenics Inc	MGNX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1675464	Thomas Spitznagel	9704 Medical Center Drive Rockville MD 20850	Sr Vp, Bpd & Manufacturing	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-08-20	7,500	$7.51	7,500	No	4	M	Direct
Common Stock	Disposition	2020-08-20	7,500	$26.87	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee stock option (right to buy)	Disposition	2020-08-20	7,500	$0.00	7,500	$7.51

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
47,147	2014-03-18	2023-09-17	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2020.
This transaction was executed in multiple trades at prices ranging from $26.54 to $27.27. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staffof the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
12.5% of the shares underlying the grant become (or became) exercisable on the date reflected and an additional 6.25% of the shares underlying the grant become (or became) exercisable on the first day of each three-month period thereafter.